Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB264 With/Without KL-A167 in Advanced HER2-negative Breast Cancer
NCT05445908Phase 2Completed
- Sponsor
- Kelun-Biotech
- Start
- Aug 2022
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab tirumotecan, tagitanlimab in triple-negative breast cancer (TNBC), breast cancer (HR-positive/HER2-negative), sponsored by Kelun-Biotech. Started Aug 2022; status: completed.
02
Drugs
sacituzumab tirumotecantagitanlimab
03
Conditions
triple-negative breast cancer (TNBC)breast cancer (HR-positive/HER2-negative)
Beyond the preview
Go deeper on NCT05445908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05445908.